



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 40546

Title: The role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma

Reviewer's code: 00070509

Reviewer's country: South Korea

Science editor: Ruo-Yu Ma

Date sent for review: 2018-08-01

Date reviewed: 2018-08-03

Review time: 1 Day

Table with 4 columns: SCIENTIFIC QUALITY, LANGUAGE QUALITY, CONCLUSION, PEER-REVIEWER STATEMENTS. It contains checkboxes for various quality grades (A-E), conclusion types (Accept, Minor revision, Major revision, Rejection), and reviewer statements regarding expertise and conflicts of interest.

SPECIFIC COMMENTS TO AUTHORS

The authors summarized the general physiological function of autophagy in cells, and reviewed the role of autophagy in tumorigenesis and metastasis in cancer. They also summarized the therapeutic strategies targeting autophagy and the mechanisms of



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

drug-resistance in HCC. So this manuscript could provide potential methods to circumvent drug resistance and anticancer therapeutic strategies for various cancers including HCC.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 40546

**Title:** The role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma

**Reviewer’s code:** 00068723

**Reviewer’s country:** Japan

**Science editor:** Ruo-Yu Ma

**Date sent for review:** 2018-08-08

**Date reviewed:** 2018-08-08

**Review time:** 16 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer’s expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Minor revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

The authors reviewed autophagy. General information was provided. Interesting point was that autophagy has two aspects-suppressing tumorigenesis, and tumor survival once cancer occurs. It would be better to describe HCC-specific aspects more clearly.



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

#### INITIAL REVIEW OF THE MANUSCRIPT

##### *Google Search:*

- The same title
- Duplicate publication
- Plagiarism
- No

##### *BPG Search:*

- The same title
- Duplicate publication
- Plagiarism
- No



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 40546

**Title:** The role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma

**Reviewer's code:** 00182114

**Reviewer's country:** Japan

**Science editor:** Ruo-Yu Ma

**Date sent for review:** 2018-08-08

**Date reviewed:** 2018-08-09

**Review time:** 17 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

This is very interesting paper. Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high.



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

The molecular mechanism of this resistance has not been fully elucidated. High mobility group box 1 (HMGB1) is a multifaceted protein that plays a key role in the proliferation, apoptosis, metastasis and angiogenesis of HCC cells. In addition, HMGB1 has been suggested to contribute to chemotherapy resistance in tumours, including lung cancer, osteosarcoma, neuroblastoma, leukaemia, and colorectal cancer. RAGE deficiency contributed to autophagy induction through activating AMPK/mTOR signaling pathway, which is important for sorafenib response. The interactions between RAGE and RAGE ligands such as high mobility group box 1 (HMGB1) and s100a4 positively increased RAGE expression. I ask one question to author. Please comment the association between HMGB1 and sorafenib resistance in HCC.

#### INITIAL REVIEW OF THE MANUSCRIPT

##### *Google Search:*

- The same title
- Duplicate publication
- Plagiarism
- No

##### *BPG Search:*

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 40546

**Title:** The role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma

**Reviewer's code:** 00053419

**Reviewer's country:** Spain

**Science editor:** Ruo-Yu Ma

**Date sent for review:** 2018-08-08

**Date reviewed:** 2018-08-12

**Review time:** 4 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer's expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Minor revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

The manuscript provides a comprehensive summary of the role of autophagy in different aspects of HCC progression and treatment. Though the most relevant studies have been revised, some discussion is needed to facilitate the interpretation to the reader,



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

who is not necessarily an expert in the field. The dual effect of autophagy is well understood but in many sections of the manuscript this concept is used in a confusing way. The authors proposed autophagy as a therapeutic target that might be used in combination with Tyr kinase inhibitors such as sorafenib but, according to the functional complexity of autophagy, a precise tumor staging should be done; is there any recommendation in this regard? Some mechanisms underlying the implication of autophagy in HCC are well described in the text; the schema on fig 1 should include at least the most relevant ones.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No